For a pharmaceutical manufacturer entering Russia or the Eurasian Economic Union, the most expensive regulatory mistakes are often made before a dossier is submitted.
A product can have a complete global CTD and still enter the wrong EAEU pathway. A technically strong dossier can be delayed because EAEU GMP status was not synchronized with filing. A variation can be classified correctly but implemented in the wrong sequence. A clinical study can be commissioned even though a biowaiver or a foreign-data/GCP-inspection pathway would have been available. A mature national registration can lose value because its post-2025 transition status was misunderstood.
Regulatory consulting is therefore not a preliminary presentation about “requirements in Russia”.
It is the work of converting a commercial objective into a defensible regulatory route, executable critical path and maintainable post-approval position.
For Pharegis, the central question is:
What has to be true—technically, procedurally and operationally—for this product to enter the target EAEU market on the required timeline and remain there without creating avoidable lifecycle debt?
Regulatory strategy begins with the business decision
The same medicinal product can require a different regulatory strategy depending on the manufacturer’s commercial objective.
Examples:
- Russia only in the first launch wave;
- simultaneous Russia, Kazakhstan and Belarus launch;
- Russian reference-state registration followed by later mutual recognition;
- addition of a new EAEU recognition state to an existing Union authorization;
- recovery of a stalled post-2025 transition procedure;
- standalone API registration in Russia plus use of the same API in EAEU medicinal-product dossiers;
- acquisition of a product whose regulatory dossier has not been independently audited;
- manufacturing-site transfer combined with GMP reinspection and CMC variations;
- introduction of a global manufacturing change into an EAEU portfolio already carrying several pending variations.
The regulatory answer should follow the business model, not the other way around.
Pharegis therefore begins with the intended market footprint, product economics, launch sequence, manufacturing model, evidence base and expected lifecycle changes before recommending a filing route.
Feasibility is not “can this product theoretically be registered?”
Almost any development programme can be expanded until it becomes technically registrable.
That is not a useful commercial answer.
A regulatory feasibility assessment should establish:
- the correct legal/scientific application basis;
- whether the available dossier can support that basis;
- the largest evidence gaps;
- EAEU GMP dependencies;
- analytical and pharmacopoeial gaps;
- clinical or bioequivalence evidence requirements;
- whether foreign clinical/nonclinical evidence is usable;
- whether additional testing or studies are avoidable;
- estimated procedural and pre-submission timeline;
- major authority-query risks;
- post-approval lifecycle obligations;
- whether the investment is proportionate to the expected market value.
The output should therefore be a go / go-with-remediation / defer / no-go recommendation, not a checklist.
A good regulatory memo converts uncertainty into decisions
For a new EAEU market-entry project, Pharegis typically reduces the problem into several decision layers.
1. Product qualification
What exactly is being registered?
Original, generic, hybrid, biosimilar, biological product, standalone API, medical device or another regulatory category?
An incorrect classification can contaminate every later decision—from evidence strategy to dossier structure and fees.
2. Geographic pathway
Which state should be the EAEU reference state?
Should Russia be entered first through the reference-state/MRP route, or should the product enter several EAEU states through DCP? Is Russia already a recognition-state opportunity under an existing EAEU dossier?
For medical devices during the current transition period, should the manufacturer use the Russian national or EAEU route?
3. Evidence pathway
Can the existing clinical and nonclinical programme be reused?
For generics: BE, BCS biowaiver, additional-strength waiver or product-specific equivalence approach?
For foreign pivotal clinical studies: ordinary EAEU acceptance or paragraph 36 GCP-inspection pathway?
For biosimilars: what residual uncertainty remains after quality comparability?
4. CMC pathway
Does the existing Module 3 reflect commercial manufacturing and current EAEU pharmacopoeial expectations?
Are specifications, methods, reference standards, stability data, sites, validation and quality documents aligned?
5. GMP and operational pathway
Which manufacturing operations must be covered by EAEU GMP status?
Does the intended inspection scope support the dossier?
When must inspection readiness begin relative to filing?
These layers are connected. The consulting value lies in resolving them as one system.
Dossier gap analysis should produce a remediation plan, not a document inventory
A basic gap assessment tells a manufacturer that a document is missing.
A useful gap assessment explains what the missing item means to the regulatory pathway.
Pharegis classifies gaps by consequence:
submission blocker — the application should not be filed until resolved;
major expert-review risk — filing is possible but likely to generate a substantive query or refusal risk;
remediable during procedure — controlled risk that can be managed without destabilizing the critical path;
lifecycle debt — approval may be possible, but the issue is likely to create an immediate post-approval variation, supply or compliance problem;
administrative/formatting gap — necessary but not scientifically determinative.
This allows management to allocate time and budget to the issues that can actually move the approval date.
The critical-path map is often more valuable than the dossier checklist
Regulatory workstreams rarely run in a clean sequence.
A typical project can involve in parallel:
- CTD remediation;
- EAEU GMP inspection preparation;
- pharmacopoeial gap assessment;
- preliminary analytical testing;
- reference-product procurement;
- BE or clinical evidence review;
- translation;
- Module 1 preparation;
- sample/reference-standard logistics;
- authority filing;
- manufacturing change planning.
The project timeline is controlled by dependencies, not by the number of tasks.
For example:
a delayed impurity standard can stop official quality testing;
a missing EAEU GMP scope can block an otherwise complete registration;
an unnecessary BE study can add months before filing;
a manufacturing change introduced during MRP can create version-control problems across states.
Pharegis therefore produces a regulatory critical-path map showing prerequisite, parallel and dependent workstreams and identifying the decisions that cannot be postponed.
CMC consulting is usually where global and EAEU dossiers diverge
A dossier accepted in the EU, US, China, India or another market is an important starting point, not proof that Module 3 is EAEU-ready.
Pharegis reviews the actual regulatory interfaces:
- 3.2.S and API/ASMF information;
- 3.2.P manufacturing and process controls;
- finished-product 3.2.P.5 control strategy;
- specifications and analytical methods;
- validation/verification;
- reference standards;
- impurity controls;
- stability;
- packaging;
- manufacturing and testing sites;
- pharmacopoeial alignment;
- quality document / normative-document strategy where applicable.
The objective is to identify where an EAEU expert is likely to ask a technically consequential question before the query is issued.
Regulatory strategy should remove unnecessary studies
A consulting project can create more value by deciding not to conduct a study than by managing a new one.
Examples include:
- a Class I or Class III BCS product suitable for a biowaiver;
- additional strengths that can be bridged scientifically;
- a conventional generic with no new nonclinical safety question;
- a biosimilar for which analytical and functional comparability leave no useful animal-study question;
- a foreign clinical programme that can be supported through the EAEU GCP-inspection route instead of repeating a local trial.
The relevant decision has to be defensible under current EAEU rules.
“Study avoidance” is not the objective. Removing scientifically unnecessary work from the regulatory critical path is.
Authority interaction should be managed as an evidence problem
An expert query is rarely just a writing task.
One question may reveal a deeper dossier inconsistency.
For example:
- a specification query may affect the quality document, analytical methods and sample testing;
- a manufacturing question may affect GMP scope and an ongoing variation;
- a clinical question may affect Module 5, product information and the benefit-risk position;
- a reference-product question may invalidate a BE strategy;
- a site-history question may trigger a GCP or GLP inspection risk.
Pharegis maps each material query to all affected dossier sections and operational consequences before drafting the response.
The aim is to answer the regulator without creating a contradiction elsewhere in the dossier.
Due diligence should test the regulatory asset, not the marketing authorization number
When a company acquires, licenses or distributes a product, the existence of a marketing authorization does not prove that the regulatory asset is healthy.
A regulatory due-diligence review can examine:
- authorization status by state;
- reference-state history;
- pending recognition procedures;
- unresolved expert commitments;
- GMP certificate scope and expiry;
- manufacturing changes not reflected in the dossier;
- open variations;
- product-information divergence;
- PV obligations;
- Module 3 maintainability;
- post-2025 national/EAEU transition status;
- reliance on fragile legacy clinical/nonclinical evidence;
- upcoming confirmation/renewal obligations.
The commercial question is not “Is it registered?”
It is:
What regulatory liabilities transfer with the product, and what investment is required to keep the authorization usable?
Lifecycle consulting begins before approval
A dossier that can be approved but cannot be maintained is not a well-designed regulatory asset.
Before first filing, it is useful to know whether the manufacturer expects within the next 12–36 months:
- new manufacturing sites;
- scale-up;
- analytical-method changes;
- new API supplier;
- new packaging;
- new strengths;
- indication extension;
- product transfer;
- corporate name/ownership changes;
- rollout into additional EAEU recognition states.
These foreseeable changes can influence the original registration strategy.
For example, a manufacturing transfer scheduled immediately after approval may justify delaying one filing or restructuring the dossier so that a major variation does not collide with mutual recognition.
Regulatory consulting should therefore incorporate the near-term product roadmap.
Russia-specific work remains where Russia genuinely remains national
The EAEU has replaced most of the old Russian national medicinal-product registration architecture for new products.
But Russia still has national regulatory workstreams that matter, including areas such as:
- standalone pharmaceutical substances manufactured for sale and entered in the Russian State Register;
- authorization and administration of clinical trials conducted in Russia;
- national execution of EAEU procedures;
- product import/sample logistics and other local administrative interfaces where national law remains applicable.
A regulatory strategy should distinguish these genuine national layers from obsolete “Russian registration” concepts that have already been replaced by EAEU law.
This distinction is one of the reasons local regulatory interpretation still matters even under a harmonized Union framework.
External regulatory function vs isolated consulting hours
For manufacturers without a full EAEU regulatory department, a project often works better when the external consultant owns the cross-functional regulatory programme rather than answering disconnected questions.
The operating model can include:
- one senior regulatory lead;
- defined manufacturer workstream owners;
- shared issue log;
- dossier decision register;
- critical-path tracker;
- authority-response tracker;
- lifecycle/change register;
- periodic management-level status report.
Pharegis can act as the local regulatory programme layer while the manufacturer retains technical ownership of manufacturing, quality, clinical development and global dossier content.
This avoids creating unnecessary local infrastructure while preserving decision control.
For established multinational teams, the model is different
Large pharmaceutical organizations usually do not need another generalist regulatory department.
They need local support where the global model encounters a difficult EAEU-specific interface.
Examples include:
- recovery of a complex Russia/EAEU procedure;
- difficult CMC deficiency response;
- EAEU GMP inspection preparation;
- post-2025 dossier-transition reconstruction;
- GCP/GLP inspection pathway;
- BCS biowaiver strategy;
- complex variation classification/grouping;
- recognition-state rollout;
- local clinical-study approval and vendor strategy.
In those projects Pharegis works as a specialist extension of the international regulatory team rather than duplicating it.
What Pharegis regulatory consulting produces
A consulting engagement should leave behind decisions and controlled work products.
Typical deliverables include:
- regulatory feasibility / market-entry memo;
- pathway decision tree;
- application-type qualification;
- dossier gap and remediation matrix;
- EAEU reference-state / recognition-state strategy;
- CMC and pharmacopoeial gap assessment;
- GMP scope and inspection-dependency map;
- clinical / BE / biowaiver / nonclinical evidence strategy;
- GCP/GLP inspection-risk assessment;
- critical-path timeline;
- authority-query strategy;
- variation/lifecycle impact assessment;
- regulatory due-diligence report;
- portfolio triage and prioritization;
- post-approval lifecycle governance plan.
The format depends on the decision the manufacturer has to make. A ten-page decision memo can be more valuable than a 200-page generic regulatory report if it identifies the right route and prevents one unnecessary study or failed filing.
Discuss a regulatory strategy before committing the budget
For an initial assessment, prepare:
- product and intended EAEU markets;
- current global registration status;
- intended launch sequence;
- CTD/eCTD or technical dossier status;
- manufacturing-site and GMP status;
- clinical/nonclinical/BE evidence status;
- planned CMC or site changes;
- target filing/launch date;
- known regulatory questions or previous authority history;
- commercial constraints that materially affect timing or scope.
Pharegis can then determine which issues require detailed technical work and which can be removed from the project before they consume budget.
The objective of regulatory consulting is not to describe the rules. It is to convert them into a sequence of decisions that gets the product to market and keeps the regulatory position maintainable.
Regulatory framework
Regulatory status reviewed: August 2026.